Surmodics | SRDX - Selling And Administration Expenses


Surmodics reported $11.4M in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.





Selling And Administration Expenses Change Date
Abbott USD 3.27B 138M Mar/2026
Align Technology USD 441.68M 23.88M Dec/2025
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 46.02M 8.84M Dec/2025
Artivion USD 55.75M 4.54M Dec/2025
Baxter International USD 761M 53M Dec/2025
Boston Scientific USD 1.83B 93M Dec/2025
EDAP TMS EUR 8.81M 1.57M Sep/2025
Edwards Lifesciences USD 602.9M 88.3M Dec/2025
Haemonetics USD 109.15M 7.54M Dec/2025
Heron Therapeutics USD 23.74M 605K Dec/2025
J&J USD 6.03B 719M Mar/2026
Merit Medical Systems USD 114.83M 7.45M Dec/2025
Mesa Laboratories USD 27.31M 380K Sep/2024
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Option Care Health USD 172.14M 33K Dec/2025
Stryker USD 2.14B 150M Dec/2025
Surmodics USD 11.4M 3.18M Jun/2025
Trinity Biotech USD 6.19M 2.18M Sep/2025